Other
Camrelizumab and apatinib
Camrelizumab and apatinib is an intervention with 6 clinical trials. Currently 2 active trials ongoing.
Total Trials
6
Max Phase
—
Type
COMBINATION PRODUCT
Molecule
—
Success Metrics
Active Trials
2(33%)
Phase Distribution
Ph phase_1
1
17%
Ph phase_3
2
33%
Ph phase_2
3
50%
Phase Distribution
1
Early Stage
3
Mid Stage
2
Late Stage
Phase Distribution6 total trials
Phase 1Safety & dosage
1(16.7%)
Phase 2Efficacy & side effects
3(50.0%)
Phase 3Large-scale testing
2(33.3%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
6
all time
Status Distribution
Active(2)
Other(4)
Detailed Status
unknown4
Recruiting2
Development Timeline
Analytics
Development Status
Total Trials
6
Active
2
Success Rate
N/A
Most Advanced
Phase 3
Trials by Phase
Phase 11 (16.7%)
Phase 23 (50.0%)
Phase 32 (33.3%)
Trials by Status
recruiting233%
unknown467%
Recent Activity
2 active trials
Showing 5 of 6
recruitingphase_3
TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma
NCT06485466
recruitingphase_3
Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCC
NCT07267806
unknownphase_2
Apatinib Combined With Camrelizumab in Treating Participants With Advanced Chordoma
NCT06140732
unknownphase_2
Camrelizumab and Apatinib for Neoadjuvant Therapy in Thyroid Cancer
NCT04612894
unknownphase_2
A Study of Carilizumab in Combination With Apatinib in Subjects With Unresectable UPS and ASPS
NCT04447274
Clinical Trials (6)
Showing 6 of 6 trials
NCT06485466Phase 3
TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma
NCT07267806Phase 3
Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCC
NCT06140732Phase 2
Apatinib Combined With Camrelizumab in Treating Participants With Advanced Chordoma
NCT04612894Phase 2
Camrelizumab and Apatinib for Neoadjuvant Therapy in Thyroid Cancer
NCT04447274Phase 2
A Study of Carilizumab in Combination With Apatinib in Subjects With Unresectable UPS and ASPS
NCT04201990Phase 1
Cryoablation Combined With Camrelizumab and Apatinib for Multiprimary Lung Cancer
All 6 trials loaded
Drug Details
- Intervention Type
- COMBINATION PRODUCT
- Total Trials
- 6